Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells.

Tumor hypoxia is a common feature of several cancers, including prostate cancer, and is associated with tumor progression, acquisition of anti-apoptotic potential and therapeutic resistance. We explored hypoxia-inducible genes and examined the effect of knockdown of a target molecule with small interference RNA (siRNA) on the proliferation of human prostate cancer cells. Human prostate cancer cell lines (LNCaP and PC-3) were cultured in normoxia (21% O2) or hypoxia (0.5% O2). Hypoxia-inducible genes were identified by cDNA microarray analysis. Metallothionein (MT) expression was assessed by real-time RT-PCR, Western blot analysis and immunohistochemical staining. siRNA was transfected to knock down MT expression, and the cell cycle and apoptosis were evaluated by flow cytometry analysis. In cDNA microarray analysis, 22 genes (including MT) were up-regulated under hypoxia. MT-1X and MT-2A were up-regulated in real-time RT-PCR. In particular, MT-2A was increased 3-fold in LNCaP and 8-fold in PC-3. The siRNA-MT-2A treatment resulted in a 20% inhibition of cell growth and induced apoptosis in both LNCaP and PC-3. In human prostate tissue, intense staining of MT was observed in cancer cells and residual cancer cells after androgen ablation therapy, while normal tissue was only stained in patches. In conclusion, MT was up-regulated under hypoxia in prostate cancer cells and overexpressed in prostate cancer tissue and residual cancer cells after androgen ablation therapy. As down-regulation of MT by siRNA inhibited cell growth and induced cell death, MT may be a new molecular target for the treatment of human prostate cancer.

[1]  P. Fraser,et al.  Sensitive detection of metallothioneins-1, -2 and -3 in tissue homogenates by immunoblotting: a method for enhanced membrane transfer and retention. , 1996, Journal of biochemical and biophysical methods.

[2]  M. Burchardt,et al.  Tumor hypoxia and the progression of prostate cancer , 2002, Current urology reports.

[3]  C. Tohyama,et al.  Metallothionein in radiation exposure: its induction and protective role. , 1999, Toxicology.

[4]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[5]  P. W. Hochachka,et al.  Going malignant: the hypoxia-cancer connection in the prostate. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  J. Lazo,et al.  Enhanced apoptosis in metallothionein null cells. , 1997, Molecular pharmacology.

[7]  M. Benson,et al.  Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells , 2003, The Prostate.

[8]  J. D. Chapman,et al.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.

[9]  J. Lazo,et al.  Metallothionein null cells have increased sensitivity to anticancer drugs. , 1995, Cancer research.

[10]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[11]  Cornelis J H van de Velde,et al.  Prognostic Significance of Metallothionein in Human Gastrointestinal Cancer 1 , 2002 .

[12]  N. Greenberg,et al.  Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. , 2003, The Journal of urology.

[13]  A. Jayasurya,et al.  Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.

[14]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[15]  R. Franklin,et al.  Inhibitory effect of zinc on human prostatic carcinoma cell growth , 1999, The Prostate.

[16]  S. Theocharis,et al.  Metallothionein expression in human neoplasia , 2004, Histopathology.

[17]  A. Shabsigh,et al.  Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids , 1999, Trends in Endocrinology & Metabolism.

[18]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[19]  Kazuto Ito,et al.  Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. , 2003, Cancer letters.

[20]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[21]  R. Franklin,et al.  Direct effect of zinc on mitochondrial apoptogenesis in prostate cells , 2002, The Prostate.

[22]  S. Garrett,et al.  Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC‐3 prostate cancer cells , 2002, The Prostate.

[23]  A. Hanlon,et al.  Hypoxic regions exist in human prostate carcinoma. , 1999, Urology.

[24]  J. Lazo,et al.  Metallothioneins and cell death by anticancer drugs. , 1995, Annual review of pharmacology and toxicology.

[25]  J. Mohler,et al.  Hypoxia increases androgen receptor activity in prostate cancer cells. , 2006, Cancer research.

[26]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  R. Chin,et al.  Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. , 1994, Cancer research.

[28]  Simon C Watkins,et al.  Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. , 1995, Cancer research.

[29]  P. Baeuerle,et al.  Hypoxia Induces c-fos Transcription via a Mitogen-activated Protein Kinase-dependent Pathway* , 1997, The Journal of Biological Chemistry.

[30]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[31]  H Watanabe,et al.  Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. , 1999, Ultrasound in medicine & biology.

[32]  A. Abdel-Mageed,et al.  Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. , 1997, Cancer gene therapy.

[33]  N. Imura,et al.  Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. , 1994, Cancer research.

[34]  Alexandra L Hanlon,et al.  Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. , 2002, Urology.

[35]  J. H. Beattie,et al.  Induction, Regulation, Degradation, and Biological Significance of Mammalian Metallothioneins , 2000, Critical reviews in biochemistry and molecular biology.

[36]  Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. , 1997, Clinical and investigative medicine. Medecine clinique et experimentale.

[37]  A. Shabsigh,et al.  Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland , 2001, Journal of cellular biochemistry.

[38]  M. Karin,et al.  Regulation of human and yeast metallothionein gene transcription by heavy metal ions. , 1993, Progress in clinical and biological research.

[39]  S. Garrett,et al.  Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.

[40]  K. Laderoute,et al.  Regulation of c-jun expression during hypoxic and low-glucose stress , 1994, Molecular and cellular biology.